Wordt geladen...
KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
Significant challenges to develop selective and effective pharmacological inhibitors for important oncoproteins like RAS continue impeding the success to treat cancers driven by such mutations. In the present study, the ABT263 and axitinib combination imposed synergistic effects on RAS-mutant colon...
Bewaard in:
| Gepubliceerd in: | Biosci Rep |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Portland Press Ltd.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6400663/ https://ncbi.nlm.nih.gov/pubmed/30674639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20181786 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|